Savara Inc. (NASDAQ:SVRA) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Shares of Savara Inc. (NASDAQ:SVRA) have earned a consensus rating of “Moderate Buy” from the ten analysts that are currently covering the firm, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, one has issued a hold recommendation, seven have given a buy recommendation and one has issued a strong buy recommendation on the company. The average 12-month price objective among brokers that have updated their coverage on the stock in the last year is $9.1250.

A number of analysts have recently commented on SVRA shares. Oppenheimer set a $10.00 price target on Savara in a research note on Tuesday, December 23rd. Citigroup reaffirmed an “outperform” rating on shares of Savara in a research note on Thursday, October 23rd. Citizens Jmp reduced their price target on shares of Savara from $11.00 to $10.00 and set a “market outperform” rating on the stock in a research report on Thursday, November 13th. HC Wainwright upped their price objective on shares of Savara from $8.00 to $10.00 and gave the company a “buy” rating in a research report on Tuesday, December 23rd. Finally, Wall Street Zen raised Savara from a “sell” rating to a “hold” rating in a research note on Saturday, November 15th.

Savara Trading Up 5.5%

Shares of SVRA traded up $0.30 on Thursday, reaching $5.65. 304,918 shares of the company’s stock were exchanged, compared to its average volume of 1,416,413. The business has a 50 day moving average price of $5.99 and a two-hundred day moving average price of $4.52. Savara has a 12 month low of $1.89 and a 12 month high of $7.01. The stock has a market capitalization of $1.15 billion, a P/E ratio of -10.68 and a beta of 0.34. The company has a current ratio of 7.65, a quick ratio of 7.65 and a debt-to-equity ratio of 0.32.

Savara (NASDAQ:SVRA) last released its earnings results on Wednesday, November 12th. The company reported ($0.14) EPS for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.01). Research analysts anticipate that Savara will post -0.45 earnings per share for the current year.

Hedge Funds Weigh In On Savara

Institutional investors and hedge funds have recently modified their holdings of the business. VR Adviser LLC raised its holdings in shares of Savara by 42.7% in the third quarter. VR Adviser LLC now owns 12,681,043 shares of the company’s stock valued at $45,271,000 after purchasing an additional 3,796,780 shares during the last quarter. Vanguard Group Inc. boosted its holdings in Savara by 20.8% during the fourth quarter. Vanguard Group Inc. now owns 10,041,647 shares of the company’s stock worth $60,551,000 after purchasing an additional 1,728,453 shares during the last quarter. Nantahala Capital Management LLC grew its position in Savara by 5.4% in the third quarter. Nantahala Capital Management LLC now owns 8,775,375 shares of the company’s stock valued at $31,328,000 after purchasing an additional 450,000 shares in the last quarter. Rosalind Advisors Inc. increased its stake in Savara by 50.7% in the 3rd quarter. Rosalind Advisors Inc. now owns 4,000,000 shares of the company’s stock valued at $14,280,000 after buying an additional 1,345,056 shares during the last quarter. Finally, Emerald Advisers LLC lifted its position in Savara by 14.4% during the 2nd quarter. Emerald Advisers LLC now owns 3,534,368 shares of the company’s stock worth $8,058,000 after buying an additional 444,155 shares in the last quarter. 87.93% of the stock is currently owned by institutional investors and hedge funds.

Savara Company Profile

Savara Inc (NASDAQ:SVRA) is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for rare respiratory diseases. The company specializes in in-licensing, advancing and potentially bringing to market novel treatments that address severe pulmonary conditions with high unmet medical need.

The company’s lead candidate, Molgradex (recombinant human granulocyte-macrophage colony-stimulating factor, or GM-CSF), is under regulatory review for the treatment of autoimmune pulmonary alveolar proteinosis (PAP), a rare lung disease characterized by the accumulation of surfactant.